Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

[1] Kuderer N(2006)Mortality, Morbidity, and Cost Associated with Febrile Neutropenia in Adult Cancer Patients CANCER 106 2258-2266

[2] Dale D(2001)Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK Pharmacoeconomics 19 1091-1102

[3] Crawford J(1998)Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Anticancer Drugs 9 899-907

[4] Cosler L(2006)Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy Breast Cancer Res Treat 100 255-262

[5] Lyman G(2005)30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study BMJ 330 217-222

[6] Brown R(1996)Filgrastim (r-metHuG-CSF): the first 10 years Blood 88 1907-1929

[7] Hutton J(2003)A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Annals of Oncology 14 29-35

[8] Burrell A(2002)Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer JOURNAL OF CLINICAL ONCOLOGY 20 727-731

[9] Brown RE(1995)Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer J Clin Oncol 13 1564-1571

[10] Hutton J(1995)Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity J Clin Oncol 13 2629-2636

[1] Kuderer N(2006)Mortality, Morbidity, and Cost Associated with Febrile Neutropenia in Adult Cancer Patients CANCER 106 2258-2266

[2] Dale D(2001)Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK Pharmacoeconomics 19 1091-1102

[3] Crawford J(1998)Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Anticancer Drugs 9 899-907

[4] Cosler L(2006)Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy Breast Cancer Res Treat 100 255-262

[5] Lyman G(2005)30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study BMJ 330 217-222

[6] Brown R(1996)Filgrastim (r-metHuG-CSF): the first 10 years Blood 88 1907-1929

[7] Hutton J(2003)A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Annals of Oncology 14 29-35

[8] Burrell A(2002)Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer JOURNAL OF CLINICAL ONCOLOGY 20 727-731

[9] Brown RE(1995)Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer J Clin Oncol 13 1564-1571

[10] Hutton J(1995)Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity J Clin Oncol 13 2629-2636